Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Protecting treatment advances for breast cancer

By Jocelyn Ulrich  |    October 31, 2022
Since the 1980s, October has been recognized as National Breast Cancer Awareness Month — an opportunity for us to unite as a community to honor those who have had breast cancer and raise awareness...   Read More

Identifying and addressing health disparities: PhRMA's first chart pack on health equity

By Kristin Williams  |    October 27, 2022
PhRMA is proud to announce the release of its first ever chart pack on health equity. This chart pack contains information on health equity in three sections: (1) A Snapshot of Health Disparities in...   Read More

In their own words: Insured Americans struggle to navigate complex coverage

By Tom Wilbur  |    October 26, 2022
A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers.   Read More

The law driving technology transfer and fostering innovation

By Megan Van Etten  |    October 24, 2022
The bipartisan Bayh-Dole Act created a framework for researchers receiving federal funds to patent and license their inventions to companies for further development and commercialization. This...   Read More

Three ways 340B is failing vulnerable patients

By Nicole Longo  |    October 20, 2022
The 340B Drug Pricing Program is 30 years old this year, but as The New York Times recently spelled out, the program has become a profit engine for large health systems over the years instead of a...   Read More

Word of the Month: Long COVID

By Michael Ybarra  |    October 19, 2022
What is Long COVID?   Read More

Many seniors are paying more for Part D medicines than their insurer

By Nicole Longo  |    October 18, 2022
For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to...   Read More

Don’t take anti-innovation, activist funded academics at their word

By Jocelyn Ulrich  |    October 18, 2022
It’s disappointing to see yet more studies published by activist-funded industry critics that fail to recognize the nature of competition in the biopharmaceutical market and use cherry-picked data to...   Read More

Biosimilar uptake is increasing and so are health savings

By Jocelyn Ulrich  |    October 17, 2022
There has been a lot of talk recently about the biosimilars marketplace and what role biosimilars play in reducing health care costs. We’re here to set the record straight about how these medicines...   Read More

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

By Michael Ybarra  |    October 13, 2022
Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...   Read More

New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance

By Emilie Signora  |    October 7, 2022
PhRMA submitted comments this week in response to the Department of Health & Human Services (HHS) proposed rule on the Nondiscrimination in Health Programs and Activities. As outlined in our...   Read More

If patients aren’t benefiting from the 340B program, who is?

By Nicole Longo  |    October 6, 2022
The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally...   Read More

Busting 3 Myths About Copay Coupons

By Katie Koziara  |    October 5, 2022
Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high...   Read More

PDUFA and BsUFA reauthorizations are wins for patients

By Stephen J. Ubl  |    October 5, 2022
America relies on the U.S. Food & Drug Administration (FDA) to keep pace with the scientific advancements happening every day in labs across the country. That’s why the recently enacted Prescription...   Read More

Mental Illness Awareness Week – A time for reflection

By Andrew Powaleny  |    October 3, 2022
Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates